All In Biotech

Drug Trial Radar · NCT07107945

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

A Randomised, Double-blind, Placebo-controlled Trial With an Open-label Extension to Assess the Pharmacokinetics, Safety, and Efficacy of Empagliflozin Tablets in Paediatric Patients With Chronic Kidney Disease (EMPA-KIDNEY® Kids)

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

135

Actual

Start

Dec 9, 2025

Primary completion

Apr 16, 2027

Study completion Apr 14, 2028

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD. Other goals of the study are to find out how empagliflozin is tolerated and handled by the body in children and adolescents with CKD. Participants are put into 2 groups randomly, which means by chance. One group takes empagliflozin and the other group takes placebo. Placebo looks like empagliflozin but does not contain any medicine. Participants are twice as likely to be in the empagliflozin group. Participants take empagliflozin or placebo as tablets once a day for 6 months. After 6 months, participants in both groups take empagliflozin as tablets once a day for 1 year. Participants are in the study for a little over a year and a half. During this time, they visit the study site about 15 times and get at least 5 phone or video calls from the site staff. At the visits, the doctors take blood and urine samples from the participants. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Chronic Kidney Disease

Interventions

  • EmpagliflozinDrug

    Empagliflozin

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Day 1 to the Week 24 visit in urine albumin-creatinine (UACR) [mg/g]Time frame: Up to week 24
  2. Change from Day 1 to the Week 24 visit in urine glucose [mmol/L]Time frame: Up to week 24

Locations

93 sites in 18 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Stanford University School of Medicine

    Palo Alto, California

  • University of California Davis

    Sacramento, California

  • University of California San Francisco

    San Francisco, California

  • University of Miami

    Miami, Florida

  • Emory University

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • Novak Center for Children's Health

    Louisville, Kentucky

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • University of Michigan

    Ann Arbor, Michigan

  • Children's Hospital of Michigan

    Detroit, Michigan

  • M Health Fairview Masonic Children's Hospital

    Minneapolis, Minnesota

  • Children's Mercy Hospitals and Clinics

    Kansas City, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Jersey Shore University Medical Center

    Neptune City, New Jersey

  • University of New Mexico

    Albuquerque, New Mexico

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Primary Children's Hospital

    Salt Lake City, Utah

  • Virginia Commonwealth University Health Systems

    Richmond, Virginia

  • Seattle Children's Hospital

    Seattle, Washington

  • University of Wisconsin

    Madison, Wisconsin

  • Hospital Italiano de Buenos Aires

    CABA, Argentina

  • Hospital de Niños Dr. Ricardo Gutierrez

    CABA, Argentina

  • Equipo Ciencia

    CABA, Argentina

  • The Children's Hospital at Westmead

    Westmead, New South Wales, Australia

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

  • Monash Children's Hospital

    Clayton, Victoria, Australia

  • The Royal Children's Hospital

    Parkville, Victoria, Australia

  • HUB CHU Brugmann

    Brussels, Belgium

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHC Mont Legia

    Liège, Belgium

  • University of Alberta Hospital (University of Alberta)

    Edmonton, Alberta, Canada

  • BC Children's Hospital

    Vancouver, British Columbia, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.